KR101930244B1 - 국소용 코르티코스테로이드 조성물 - Google Patents

국소용 코르티코스테로이드 조성물 Download PDF

Info

Publication number
KR101930244B1
KR101930244B1 KR1020167028054A KR20167028054A KR101930244B1 KR 101930244 B1 KR101930244 B1 KR 101930244B1 KR 1020167028054 A KR1020167028054 A KR 1020167028054A KR 20167028054 A KR20167028054 A KR 20167028054A KR 101930244 B1 KR101930244 B1 KR 101930244B1
Authority
KR
South Korea
Prior art keywords
composition
betamethasone
skin
water
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167028054A
Other languages
English (en)
Korean (ko)
Other versions
KR20160144377A (ko
Inventor
사테쉬 칸다빌리
프라이야다르샨니 사후카르
프랭클린 오쿠무
Original Assignee
프로미우스 파마 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로미우스 파마 엘엘씨 filed Critical 프로미우스 파마 엘엘씨
Publication of KR20160144377A publication Critical patent/KR20160144377A/ko
Application granted granted Critical
Publication of KR101930244B1 publication Critical patent/KR101930244B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020167028054A 2014-03-11 2015-03-11 국소용 코르티코스테로이드 조성물 Expired - Fee Related KR101930244B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461951165P 2014-03-11 2014-03-11
US61/951,165 2014-03-11
PCT/US2015/020031 WO2015138650A1 (en) 2014-03-11 2015-03-11 Topical corticosteroid compositions

Publications (2)

Publication Number Publication Date
KR20160144377A KR20160144377A (ko) 2016-12-16
KR101930244B1 true KR101930244B1 (ko) 2018-12-18

Family

ID=52727460

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167028054A Expired - Fee Related KR101930244B1 (ko) 2014-03-11 2015-03-11 국소용 코르티코스테로이드 조성물
KR1020167030914A Expired - Fee Related KR101930246B1 (ko) 2014-03-11 2015-09-09 국소용 코르티코스테로이드 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167030914A Expired - Fee Related KR101930246B1 (ko) 2014-03-11 2015-09-09 국소용 코르티코스테로이드 조성물

Country Status (13)

Country Link
US (4) US20150258119A1 (cg-RX-API-DMAC7.html)
EP (2) EP3116473B1 (cg-RX-API-DMAC7.html)
JP (2) JP6487949B2 (cg-RX-API-DMAC7.html)
KR (2) KR101930244B1 (cg-RX-API-DMAC7.html)
CN (1) CN106659682B (cg-RX-API-DMAC7.html)
AU (2) AU2015229403B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016021023A2 (cg-RX-API-DMAC7.html)
CA (2) CA2945943C (cg-RX-API-DMAC7.html)
EA (2) EA201691808A8 (cg-RX-API-DMAC7.html)
ES (1) ES2857602T3 (cg-RX-API-DMAC7.html)
MX (2) MX381164B (cg-RX-API-DMAC7.html)
WO (2) WO2015138650A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606704B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2637447T3 (es) 2009-08-31 2017-10-13 Dr. Reddy's Laboratories Ltd. Formulaciones tópicas que contienen un esteroide
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
WO2017091168A1 (en) * 2015-11-28 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. A topical spray comprising isoconazole nitrate and difluocortolone valerate
WO2017123744A1 (en) * 2016-01-12 2017-07-20 Grace Therapeutics Llc Betamethasone oral spray formulation and method of use to treat ataxia
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US20180028766A1 (en) * 2016-07-27 2018-02-01 Sun Pharmaceutical Industries Limited Touch-free topical spray of halobetasol
JP2019529555A (ja) 2016-09-21 2019-10-17 アヴェクシン エーエス 医薬組成物
US10543177B2 (en) 2017-04-11 2020-01-28 Kevin Mrohs Composition and method for treating skin conditions
US11620886B2 (en) 2018-02-19 2023-04-04 Invue Security Products Inc. Merchandise security system with inductive charging
CA3114363A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of steroids and large molecules
JP7412292B2 (ja) * 2019-07-10 2024-01-12 積水化学工業株式会社 製剤
WO2021080527A1 (en) * 2019-10-24 2021-04-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. Topical pharmaceutical compositions containing difluocortolone and isoconazole
US20230057282A1 (en) * 2020-02-11 2023-02-23 Taro Pharmaceutical Industries Ltd. Compositions comprising desoximetasone and tazarotene
US11382863B2 (en) * 2020-03-04 2022-07-12 Somerset Therapeutics Llc Injectable suspension comprising an insoluble corticosteroid and a soluble corticosteroid
CN113092601B (zh) * 2021-03-02 2022-12-20 苏州市药品检验检测研究中心 一种化妆品中倍他米松17-丙酸酯及倍他米松21-丙酸酯的检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20110305643A1 (en) * 2010-06-11 2011-12-15 Precision Dermatology, Inc. High Oil-Content Emollient Aerosol Foam Compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892856A (en) 1974-04-10 1975-07-01 Squibb & Sons Inc Topical steroid formulation
US3934013A (en) 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
US4343798A (en) 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US5422361A (en) * 1989-12-20 1995-06-06 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
IT1247529B (it) 1991-04-24 1994-12-17 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale
DE19536246A1 (de) 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
IL152486A0 (en) * 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
AU2004313285A1 (en) * 2003-12-16 2005-09-29 Foamix Ltd Oleaginous pharmaceutical and cosmetic foam
US8460641B2 (en) * 2004-08-31 2013-06-11 Stiefel Research Australia Pty Ltd Microemulsion process and composition
CN101048136B (zh) * 2004-08-31 2011-06-22 施蒂福研究澳大利亚股份有限公司 微乳化和亚微米乳化方法和组合物
US20060246098A1 (en) * 2005-03-16 2006-11-02 Srinivasa Rao Stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
MX2007013230A (es) 2005-04-25 2008-04-17 Dow Pharmaceutical Sciences Y Uso de una formulacion en aerosol de clobetasol para tratar psoriasis.
GB2443162B (en) 2006-10-28 2011-02-09 Nupharm Lab Ltd Betamethasone spray
ES2637447T3 (es) * 2009-08-31 2017-10-13 Dr. Reddy's Laboratories Ltd. Formulaciones tópicas que contienen un esteroide
US8871184B2 (en) * 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
NL2004437C2 (en) * 2010-03-19 2011-09-20 Forte Iq B V Spray-pumpable comprising composition suitable for topical skin application.
IN2015DN01009A (cg-RX-API-DMAC7.html) * 2012-08-10 2015-06-12 Asahi Glass Co Ltd
WO2014145067A1 (en) * 2013-03-15 2014-09-18 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment
US10111956B2 (en) * 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20110305643A1 (en) * 2010-06-11 2011-12-15 Precision Dermatology, Inc. High Oil-Content Emollient Aerosol Foam Compositions

Also Published As

Publication number Publication date
US20150258119A1 (en) 2015-09-17
EP3197432A4 (en) 2018-10-10
MX2016011842A (es) 2017-02-02
EA201691808A8 (ru) 2017-04-28
US20180250312A1 (en) 2018-09-06
JP2017508802A (ja) 2017-03-30
WO2015138650A1 (en) 2015-09-17
JP6487949B2 (ja) 2019-03-20
KR20170023791A (ko) 2017-03-06
AU2015229403B2 (en) 2019-05-02
EA201691808A1 (ru) 2017-02-28
EP3116473B1 (en) 2020-12-30
WO2016144381A1 (en) 2016-09-15
US20200230155A1 (en) 2020-07-23
EP3116473A1 (en) 2017-01-18
AU2015229403A1 (en) 2016-10-27
MX381164B (es) 2025-03-12
CA2945943C (en) 2020-10-27
KR20160144377A (ko) 2016-12-16
EP3197432A1 (en) 2017-08-02
ZA201606704B (en) 2019-07-31
CA2946201C (en) 2020-10-27
CA2946201A1 (en) 2016-09-15
JP6535735B2 (ja) 2019-06-26
AU2015385750A1 (en) 2016-10-27
JP2017530974A (ja) 2017-10-19
CA2945943A1 (en) 2015-09-17
KR101930246B1 (ko) 2018-12-18
MX2016011841A (es) 2017-02-02
BR112016021023A8 (pt) 2018-01-30
CN106659682B (zh) 2020-12-29
US20160030450A1 (en) 2016-02-04
ES2857602T3 (es) 2021-09-29
EA201692334A1 (ru) 2018-02-28
CN106659682A (zh) 2017-05-10
BR112016021023A2 (pt) 2021-09-14
AU2015385750B2 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
KR101930244B1 (ko) 국소용 코르티코스테로이드 조성물
US10905697B2 (en) Topical formulations comprising a steroid

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221213

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221213